A single MXene-based optical gate switches between seven Boolean logic functions via voltage, enabling trainable photonic ...
A heat-resistant titanium dioxide scaffold makes it possible to nanoimprint reconfigurable phase-change metasurfaces over ...
Study will highlight novel iNKT cell-based combinations in checkpoint-refractory diseaseData expected to inform immune modulation, treatment ...
We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...
Immune Modulation, Inc., a California-based biotech company founded in 1995, is translating a plant-derived compound into a ...
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat ...
Merck initiates pivotal phase 2b/3 trial of Tiespectus, an investigational bispecific tie2 agonist/VEGF inhibitor, to treat neovascular age-related macular degeneration: Rahway, N ...
SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial ...
ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 ...
A light pulse is technically empty, yet capable of carrying a trillion photons in a single burst. That is part of what makes ...
A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results